Antibodies and alternative antibody molecules (e.g. nanobodies) are increasingly important classes of therapeutics characterized by high binding specificity and affinity for targets. However, developing antibody therapeutics is time consuming and costly. My research aims to address this by developing machine learning methods to improve computational antibody design against a desired epitope. In particular, I will be focusing on in silico antibody affinity maturation and humanization.